Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.71 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | FYN | P06241 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.47 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.47 |
| ▸ | TOP2A | P11388 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26378204 | 0.92 | HPGD (0.64) | HPGDTP53BP1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL11994517 | 0.92 | TP53BP1 (0.62) | HPGDTP53BP1ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL26378200 | 0.86 | HPGD (0.70) | HPGDTP53BP1FYN | |
| SCHEMBL26378195 | 0.86 | HPGD (0.70) | HPGDTP53BP1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL21345718 | 0.84 | TP53BP1 (0.67) | HPGDTP53BP1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL27317323 | 0.84 | PARP1 (0.59) | HPGDTP53BP1FYN | |
| SCHEMBL23490253 | 0.83 | TP53BP1 (0.70) | HPGDTP53BP1HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL18232445 | 0.83 | TP53BP1 (0.70) | HPGDTP53BP1HSD17B10SMN1; SMN2KMT2A | |
| SCHEMBL10080947 | 0.83 | TP53BP1 (0.70) | HPGDTP53BP1ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL842218 | 0.82 | NPC1 (0.59) | HPGDKDM4EALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| WO-2010030967-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH LLC (US) | 2010-03-18 | — | — | WO | disclosed |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | WYETH (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | HPGD 4110/4885TP53BP1 3916/4885KDM4E 2800/4885 |
| US-20100068204-A1 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS | MTOR, RICTOR, PIK3CA | HPGD 2472/4885TP53BP1 2082/4885KDM4E 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.